BUSINESS COMBINATION AND DECONSOLIDATION OF SUBSIDIARY (Details 5) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Net revenues	$ 6,555	$ 2,051
Net loss	(13,193)	$ (30,621)
Cure Pharmaceutical [Member]
Net revenues	1,049
Net loss	$ (29,059)
Net loss attributable to Cure per common share, basic and dilued	$ (0.65)
Pro forma Adjustment [Member]
Net revenues	$ (34)
Net loss	162
Consolidated Pro Forma [Member]
Net revenues	7,743
Net loss	$ (31,948)
Net loss attributable to Cure per common share, basic and dilued	$ (0.68)
Sera Labs [Member]
Net revenues	$ 6,728
Net loss	$ (3,051)
Net loss attributable to Cure per common share, basic and dilued	$ (0.26)